Bone Biologics (BBLGW) Total Debt (2013 - 2021)

Bone Biologics (BBLGW) has reported Total Debt for 9 consecutive years, with $12.8 million the latest figure, recorded in Q3 2021.

• On a quarterly basis, Total Debt rose 10.07% year-over-year to $12.8 million in Q3 2021; TTM through Sep 2021 was $12.8 million, a 10.07% increase from a year earlier, with the FY2020 full-year figure at $11.7 million, up 3.46% from the prior year.
• Total Debt was $12.8 million for Q3 2021 at Bone Biologics, up from $12.5 million in the prior quarter.
• Over five years, Total Debt peaked at $23.0 million in Q3 2017 and troughed at $8.2 million in Q4 2017.
• A 5-year average of $12.4 million and a median of $11.4 million in 2020 frame the typical range for Total Debt.
• Across the five-year window, Total Debt surged 53.64% in 2017 and tumbled 60.85% in 2018, its largest moves.
• Over 5 years, Total Debt stood at $8.2 million in 2017, then gained by 9.36% to $9.0 million in 2018, then climbed by 25.78% to $11.3 million in 2019, then increased by 3.46% to $11.7 million in 2020, then grew by 9.01% to $12.8 million in 2021.
• The last three Total Debt figures came in at $12.8 million (Q3 2021), $12.5 million (Q2 2021), and $11.9 million (Q1 2021), per Business Quant data.